In the Claims

1. (Original) A compound having general formula I:



I

where

Q^- represents the conjugate base of a pharmaceutically suitable organic or inorganic acid;

R_1 and R'_1 represent, independently of each other, a radical selected from the group formed by H and C_{1-6} alkyl optionally substituted by trifluoromethyl, hydroxyl or alkoxyl;

R_2 and R'_2 represent, independently of each other, an aryl radical optionally substituted by halogen, trifluoromethyl, hydroxyl, C_{1-6} alkyl, amino or alkoxyl;

R_3 and R'_3 represent, independently of each other, either a radical selected from the group formed by H, halogen, trifluoromethyl, hydroxyl, amino, alkoxyl and C_{1-6} alkyl optionally substituted by trifluoromethyl, hydroxyl, amino or alkoxyl, or together with R_4 and R'_4 respectively, and independently of each other, a -CH=CH-CH=CH- radical optionally substituted by halogen, trifluoromethyl, hydroxyl, C_{1-6} alkyl, amino or alkoxyl;

R_4 and R'_4 represent, independently of each other, either a radical selected from the group formed by H and C_{1-6} alkyl optionally substituted by halogen, trifluoromethyl, hydroxyl, amino or alkoxyl, or together with R_3 and R'_3 respectively, and independently of each other, a -CH=CH-CH=CH- radical optionally substituted by halogen, trifluoromethyl, hydroxyl, C_{1-6} alkyl, amino or alkoxyl; and

A represents a spacer group.

2. (Currently Amended) A compound according to claim 1, characterized in that spacer A has a formula selected from the group consisting of:



II;

~~wherein m, n and p represent integers which can have the following values: m = 0, 1; n= 0, 1-10; p= 0, 1; with the condition that m, n and p do not take the value of zero at the same time.~~



III;



IV;



V; and



VI

wherein m, n and p represent integers which can have the following

values: m = 0, 1; n= 0, 1-10; p= 0, 1; with the condition that m, n and p do not take the value of zero at the same time.

3. (Currently Amended) A compound according to ~~previous claims~~ claim 1, characterized in that R_2 and R'_2 represent, independently of each other, a phenyl radical optionally substituted by halogen, trifluoromethyl, hydroxyl, C_{1-6} alkyl, amino and alkoxyl.

4. (Original) A compound according to claim 3, characterized in that R_1 and R'_1 represent a methyl radical, and in that R_2 and R'_2 represent, independently of each other, a phenyl radical optionally substituted by one or more halogen substituents.

5. (Currently Amended) A compound according to ~~the previous claims~~ claim 1, characterized in that both R_3 and R_4 and R'_3 and R'_4 together represent, although independently of each other, a -CH=CH-CH=CH- radical optionally substituted by one or more halogen substituents.

6. (Currently Amended) A compound according to claim 1, characterized in that it has the following substituents:

No.	~~R_3, R_4*~~ (R_3 , R_4) and (R'_3, R'_4)	NR_1R_2 and $NR'_1R'_2$	A	Code
1	H, H			ACG560B
2	H, H			ACG416B
3	H, H			ACG548B
4	H, H			ACG604A

5	-(CH=CH)$_2$-			RSM964A
6	-C^{5}H=C^{6}H- C^{7}Cl=C^{8}H-			RSM820C
7	-(CH=CH)$_2$-			RSM932A
8	-C^{5}H=C^{6}H- C^{7}Cl=C^{8}H-			RSM824B
9	-(CH=CH)$_2$-			RSM936A
10	-C^{5}H=C^{6}H- C^{7}Cl=C^{8}H-			RSM828B

~~*R_3 and R_4 can mean either each one is hydrogen or both form a single radical.~~

7. (Original) A compound according to claim 6, characterized in that Q represents Br (bromide) or F_6P (hexafluorophosphate).

8. (Currently Amended) A pharmaceutical formulation comprising at least one compound defined in claim ~~claims~~ 1 ~~to 7~~ as an active ingredient.

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Currently Amended) A process for preparing a compound according to claim 1 comprising reacting:

a) the corresponding heterocyclic derivative of formula VII and the dihalogenated derivative AX_2 (where X represents the halogen atom: Cl, Br or I) in 2:1 molar amounts in an organic solvent or,

b) the corresponding heterocyclic derivative of formula VII and the dihalogenated derivative AX_2 (where X represents the halogen atom: Cl, Br or I) in a 1:1 molar ratio in an organic solvent, in order to give a monoquaternized product which is again reacted with another different heterocyclic derivative molecule, in a 1:1 molar ratio, using an organic solvent that is more polar than the first one,

wherein the compound having general formula VII is characterized by



VII

where

R_1 represents a radical selected from the group formed by H and C_{1-6} alkyl optionally substituted by trifluoromethyl, hydroxyl or alkoxyl;

R_2 represents an aryl radical optionally substituted by halogen, trifluoromethyl, hydroxyl, C_{1-6} alkyl, amino or alkoxyl

R_3 represents either a radical selected from the group formed by H, halogen, trifluoromethyl, hydroxyl, amino, alkoxyl and C_{1-6} alkyl optionally substituted by trifluoromethyl, hydroxyl, amino or alkoxyl, or together with R_4 a -CH=CH-CH=CH- radical optionally substituted by halogen, trifluoromethyl, hydroxyl, C_{1-6}, alkyl, amino or alkoxyl;

R_4 represents either a radical selected from the group formed by H, and C_{1-6} alkyl optionally substituted by halogen, trifluoromethyl, hydroxyl, amino or alkoxyl, or together with R_3

a -CH=CH-CH=CH- radical optionally substituted by halogen, trifluoromethyl, hydroxyl, C_{1-6} alkyl, amino or alkoxyl.

14. (Cancelled)

15. (Currently Amended) Compounds according to claim ~~14~~ 13 having formulas:

4-(4-chloro-*N*-methylanilino)quinoline



VIII A

and 7-chloro-4-(4-chloro-*N*-methylanilino)quinoline



VIII B.

16. (New) Method for treating breast, lung, colorectal and/or pancreatic cancer in a patient in need of such treatment, said method comprising administering a compound according to claim 1.

17. (New) Method for an antiviral, antiparasitic and/or antifungal treatment in a patient in need of such treatment, said method comprising administering a compound according to claim 1.